new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12016009593904/07/16 Neoadjuvant use of antibody-drug conjugates
22016009041303/31/16 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
32016009042303/31/16 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
42016008200303/24/16 Immunoconjugates with an intracellularly-cleavable linkage
52016006988503/10/16 Detection of early-stage pancreatic adenocarcinoma
62016006070703/03/16 Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
72016004562602/18/16 Methods and compositions for improved labeling of targeting peptides
82016003994102/11/16 Immunotherapy of autoimmune disorders using antibodies which target b-cells
92016003200302/04/16 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
102016003200402/04/16 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
112016003200802/04/16 Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
122016002421201/28/16 Humanized anti-hla-dr antibodies
132016000091501/07/16 Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells
142015036698812/24/15 Antibody-drug conjugates and uses thereof
152015036836212/24/15 Anti-histone therapy for vascular necrosis in severe glomerulonephritis
162015034308712/03/15 Class i anti-cea antibodies and uses thereof
172015034457312/03/15 Humanized anti-cd22 antibody
182015032087211/12/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
192015031528911/05/15 Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
202015030624310/29/15 Antibody-sn-38 immunoconjugates with a cl2a linker
212015030624410/29/15 Anthracycline-antibody conjugates for cancer therapy
222015030752410/29/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
232015028326410/08/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
242015025211009/10/15 Anti-cd19 antibodies
252015023997408/27/15 Humanized rfb4 anti-cd22 antibody
262015022419208/13/15 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
272015021699708/06/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
282015021700608/06/15 Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
292015020231907/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
302015020232007/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
312015019665307/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
322015019665407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
332015019666107/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
342015019666207/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
352015019666407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
362015019666507/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
372015019666607/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
382015018263307/02/15 Immunoconjugates with an intracellularly-cleavable linkage
392015018388007/02/15 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
402015017426906/25/15 Immunoconjugates with an intracellularly-cleavable linkage
412015017427006/25/15 Immunoconjugates with an intracellularly-cleavable linkage
422015016507506/18/15 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
432015016507606/18/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
442015016665906/18/15 Humanized l243 antibodies
452015016666906/18/15 Anti-cd74 immunoconjugates and methods of use
462015015096906/04/15 Chimeric and humanized anti-histone antibodies
472015013276805/14/15 Anti-pancreatic cancer antibodies
482015012538605/07/15 Humanized anti-ceacam5 antibody and uses thereof
492015011127904/23/15 Class i anti-cea antibodies and uses thereof
502015009445604/02/15 Anthracycline-antibody conjugates for cancer therapy
512015008648203/26/15 Dye conjugated peptides for fluorescent imaging
522015005743202/26/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
532015003868602/05/15 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
542015001851601/15/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
552014037717312/25/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
562014037717712/25/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
572014037728712/25/14 Anti-trop-2 antibody-drug conjugates and uses thereof
582014036992712/18/14 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
592014028686009/25/14 Immunoconjugates with an intracellularly-cleavable linkage
602014028686109/25/14 Rs7 antibodies
612014023420908/21/14 Chimeric and humanized anti-histone antibodies
622014022717808/14/14 Humanized anti-hla-dr antibodies
632014022717908/14/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
642014022718008/14/14 Antibody-sn-38 immunoconjugates with a cl2a linker
652014022854108/14/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
662014021991408/07/14 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
672014021995608/07/14 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
682014021242507/31/14 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
692014019335907/10/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
702014017829406/26/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
712014017006506/19/14 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
722014015427306/05/14 Anthracycline-antibody conjugates for cancer therapy
732014014738205/29/14 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
742014014092405/22/14 Humanized l243 antibodies
752014012003505/01/14 Rs7 antibodies
762014011286404/24/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
772014011286504/24/14 Anti-cd19 antibodies
782014010581904/17/14 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
792014009925804/10/14 Camptothecin-binding moiety conjugates
802014008683003/27/14 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
812014008683203/27/14 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
822014007962903/20/14 Class i anti-cea antibodies and uses thereof
832014005806702/27/14 Immunoconjugates with an intracellularly-cleavable linkage
842014004463902/13/14 Antibody therapy
852014004464002/13/14 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
862014003754302/06/14 Anti-pancreatic cancer antibodies
872014003826102/06/14 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
882014003828402/06/14 Mammalian cell lines for increasing longevity and protein yield from a cell culture
892014001716801/16/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
902014001719701/16/14 Anti-cd19 antibodies
912014000407801/02/14 Immunoconjugates with an intracellularly-cleavable linkage
922013031582111/28/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
932013030917711/21/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
942013021656108/22/13 Immunoconjugates with an intracellularly-cleavable linkage
952013020935608/15/13 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
962013021104408/15/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
972013017749807/11/13 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
982013017752607/11/13 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
992013017106407/04/13 Anti-cd74 immunoconjugates and methods of use
1002013017106507/04/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1012013017117607/04/13 Anthracycline-antibody conjugates for cancer therapy
1022013016421406/27/13 Antibody-based depletion of antigen-presenting cells and dendritic cells
1032013016478306/27/13 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1042013015669106/20/13 Antibody therapy
1052013014278706/06/13 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
1062013014329606/06/13 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1072013012191305/16/13 Anti-cd19 antibodies
1082013012347305/16/13 Bispecific antibody targeting a complement factor or complement regulatory protein
1092013009503404/18/13 Anti-cd74 immunoconjugates and methods
1102013009045804/11/13 Immunoconjugates with an intracellularly-cleavable linkage
1112013007818203/28/13 Structural variants of antibodies for improved therapeutic characteristics
1122013007826303/28/13 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
1132013007132003/21/13 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1142013007140603/21/13 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
1152013007265903/21/13 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1162013003986102/14/13 Dye conjugated peptides for fluorescent imaging
1172013003449202/07/13 Class i anti-cea antibodies and uses thereof
1182012032856412/27/12 Camptothecin-binding moiety conjugates
1192012032863412/27/12 Immunoconjugates with an intracellularly-cleavable linkage
1202012032155312/20/12 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
1212012028217811/08/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1222012027610011/01/12 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1232012023095309/13/12 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1242012021496908/23/12 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1252012019632608/02/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1262012018954207/26/12 Anti-cd19 antibodies
1272012018347207/19/12 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1282012018355007/19/12 Therapeutic using a bispecific antibody
1292012014908506/14/12 Fusion proteins containing recombinant cytotoxic rnases
1302012014137206/07/12 Rs7 antibodies
1312012014137506/07/12 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
1322012013492005/31/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1332012011455605/10/12 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1342012010723505/03/12 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1352012008829904/12/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1362012008261704/05/12 Immunoconjugates with an intracellularly-cleavable linkage
1372012007672703/29/12 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1382012006399303/15/12 Therapeutic and diagnostic conjugates for use with multispecific antibodies
1392012003979702/16/12 Antibody therapy
1402012004043102/16/12 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1412012003418502/09/12 Anti-cd20 antibodies and fusion proteins therof and methods of use
1422011031153112/22/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1432011030563112/15/11 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1442011030006612/08/11 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1452011029351312/01/11 Immunoconjugates with an intracellularly-cleavable linkage
1462011028691811/24/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1472011028080111/17/11 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1482011027470411/10/11 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1492011025605310/20/11 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1502011024384110/06/11 Antibody-based depletion of antigen-presenting cells and dendritic cells
1512011024454610/06/11 Internalizing anti-cd74 antibodies and methods of use
1522011023630409/29/11 Structural variants of antibodies for improved therapeutic characteristics
1532011023640409/29/11 Methods for protein expression in mammalian cells in serum-free medium
1542011022940709/22/11 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1552011022364509/15/11 Multivalent carriers of bi-specific antibodies
1562011019502308/11/11 Internalizing anti-cd74 antibodies and methods of use
1572011018908508/04/11 Antibody therapy
1582011018926808/04/11 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1592011017112607/14/11 Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1602011016507207/07/11 Detection of early-stage pancreatic adenocarcinoma
1612011016507307/07/11 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1622011011701005/19/11 Methods and compositions for administering therapeutic and diagnostic agents
1632011011710505/19/11 Method of treating immune disease using b-cell antibodies
1642011011085405/12/11 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1652011007623303/31/11 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1662011007015503/24/11 Anti-cd74 immunoconjugates and methods
1672011007015603/24/11 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1682011006465303/17/11 Class i anti-cea antibodies and uses thereof
1692011005248903/03/11 Anti-cd19 antibodies
1702010031116212/09/10 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1712010028490611/11/10 Internalizing anti-cd74 antibodies and methods of use
1722010027263610/28/10 Anti-cd74 immunoconjugates and methods of use
1732010026649610/21/10 Anti-cd74 immunoconjugates and methods of use
1742010026649710/21/10 Internalizing anti-cd74 antibodies and methods of use
1752010023377909/16/10 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1762010022688409/09/10 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1772010022117509/02/10 Antibody therapy
1782010022117709/02/10 Rs7 antibodies
1792010021666208/26/10 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1802010020296108/12/10 D-amino acid peptides
1812010019626608/05/10 Humanized anti-hla-dr antibodies
1822010019626708/05/10 Humanized l243 antibodies
1832010019698908/05/10 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1842010018964107/29/10 Novel strategies for improved cancer vaccines
1852010015880206/24/10 Chimeric, human and humanized anti-csap monoclonal antibodies
1862010015880306/24/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1872010013662606/03/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1882010010458904/29/10 Immunoconjugates with an intracellularly-cleavable linkage
1892010007484003/25/10 Anthracycline-antibody conjugates for cancer therapy
1902010006813603/18/10 Anti-cd19 antibodies
1912010004054102/18/10 Structural variants of antibodies for improved therapeutic characteristics
1922010003473802/11/10 Structural variants of antibodies for improved therapeutic characteristics
1932010001504601/21/10 Camptothecin-binding moiety conjugates
1942010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1952010000885501/14/10 Production and use of novel peptide-based agents with bispecific antibodies
1962010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1972009030458012/10/09 Anti-pancreatic cancer antibodies
1982009029903312/03/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1992009029109311/26/09 Immunoconjugates with an intracellularly-cleavable linkage
2002009028575211/19/09 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
2012009027464911/05/09 Bispecific antibody point mutations for enhancing rate of clearance
2022009025273110/08/09 Multivalent carriers of bi-specific antibodies
2032009025317910/08/09 Mammalian cell lines for increasing longevity and protein yield from a cell culture
2042009024613010/01/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2052009024613110/01/09 Production and use of novel peptide-based agents for use with bi-specific antibodies
2062009024621410/01/09 Fusion proteins containing recombinant cytotoxic rnases
2072009023875709/24/09 Methods and compositions for administering therapeutic and diagnostic agents
2082009024003709/24/09 Humanized antibodies and methods of humanizing antibodies
2092009018597407/23/09 Chimeric, human and humanized anti-granulocyte antibodies and methods of use
2102009015516606/18/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2112009015525306/18/09 Anti-cd20 antibodies and fusion proteins therof and methods of use
2122009011114304/30/09 Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
2132009009259804/09/09 Antibody therapy
2142010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
2152010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###